Sermorelin — 5 mg

Sermorelin corresponds to GHRH(1–29), a shortened version of growth-hormone-releasing hormone retaining the hormone’s biologically active amino-terminal region. Its action is upstream of growth hormone: it engages pituitary GHRH receptors and promotes endogenous GH secretion. Umbrella’s description connects the peptide with historical pediatric growth-hormone-deficiency work and studies in older adults. This mechanism distinguishes it from recombinant GH and from compounds that stimulate the ghrelin receptor.

A clinical investigation in eleven older men examined GH secretion, strength, body composition, and metabolic measurements. The authors reported higher nocturnal GH output and improvement in selected strength or endurance tests, but no change in IGF-I, body weight, or measured muscle and fat mass during that study. Those findings help explain the interest in age-related endocrine function without turning every proposed anti-aging outcome into a reported result. For research descriptions, the most accurate themes are pituitary responsiveness, GH pulsatility, and downstream endocrine physiology. The laboratory vial is described by its seller as a research reagent, separately from historical pharmaceutical formulations.